Cargando…

Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review

The scientific landscape of treatments for type 2 diabetes (T2D) has changed rapidly in the last decade with newer treatments becoming available. However, a large proportion of people with T2D are not able to achieve glycaemic goals because of clinical inertia. The majority of T2D management is in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernando, Kevin, Bain, Stephen C., Holmes, Patrick, Jones, Philip Newland, Patel, Dipesh C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312211/
https://www.ncbi.nlm.nih.gov/pubmed/34309808
http://dx.doi.org/10.1007/s13300-021-01116-9